What's in Tampa Bay Uveitis Center, LLC's pipeline?

Tampa Bay Uveitis Center, LLC has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Tampa Bay Uveitis Center, LLC's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/tampa-bay-uveitis-center-llc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Tampa Bay Uveitis Center, LLC — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tampa Bay Uveitis Center, LLC pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION	H.P. ACTHAR SUBCUTANEOUS GEL INJECTION	marketed	Corticotropin (ACTH) analog	Melanocortin receptors (primarily MC2R on adrenal cortex; also MC1R, MC3R, MC4R, MC5R on immune cells)	Immunology / Rheumatology / Ophthalmology

Therapeutic area mix

Immunology / Rheumatology / Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Tampa Bay Uveitis Center, LLC:

Cite this brief

Drug Landscape (2026). Tampa Bay Uveitis Center, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tampa-bay-uveitis-center-llc. Accessed 2026-05-18.